Oregon Measure 109 — Psilocybin therapy is legal and regulated in Oregon. Find a licensed facilitator →
The most credible source for psilocybin therapy information. For veterans, clinicians, and anyone who deserves real answers — not noise.
A landmark open-label trial found that two psilocybin sessions, combined with supportive psychotherapy, produced large and sustained decreases in depression and anxiety in adults with major depressive disorder — with effect sizes substantially larger than antidepressants.
Read the brief →New imaging research reveals how a single psilocybin session disrupts the brain's most entrenched patterns — and why that disruption may be the key to lasting change.
A precise, plain-language breakdown of the law that made Oregon the first state to create a regulated psilocybin therapy framework — who can access, and what the law prohibits.
An evidence review of the largest randomized controlled trial on psychedelic-assisted therapy for PTSD — findings, limitations, and what they mean for veterans seeking access today.
Treatment-resistant PTSD affects hundreds of thousands of veterans and first responders. This section compiles the full body of research on psilocybin-assisted therapy — MAPS trial data, the federal research landscape, and how to access legal services in Oregon. Written for the people who need this most, and for the families searching alongside them.
New imaging research reveals how a single psilocybin session disrupts the brain's most entrenched patterns — and why that disruption may be the key to lasting change.
The brain's default mode network — a loosely connected constellation of regions active when we're not focused on any external task — has quietly become one of the most studied targets in psychiatry. It is the network of rumination, of self-referential thought, of the stories we tell ourselves about who we are. And in people with depression, PTSD, and addiction, it is chronically, rigidly overactive.
In fMRI studies at Imperial College London and Johns Hopkins, researchers have observed that psilocybin dramatically reduces the functional connectivity of the default mode network — not permanently, but for several hours during the experience. The regions that normally talk to each other in tight, well-worn loops go temporarily quiet. Other regions, previously disconnected, begin communicating in novel patterns. [1]
The DMN is not a single structure but a distributed system: the medial prefrontal cortex, the posterior cingulate cortex, the angular gyrus, and the hippocampus are its primary nodes. In people with depression or PTSD, the DMN becomes pathologically self-focused. The default mode loops aren't generating useful reflection — they're generating rumination. [2]
Psylowise connects you with Oregon-licensed psilocybin service centers and facilitators operating under OHA regulation.
The implications for clinical treatment are significant. If depression and PTSD are characterized by an inability to update rigid, maladaptive beliefs about the self and the world, then a therapeutic window that temporarily loosens those beliefs — combined with skilled psychotherapeutic support — creates an opportunity for lasting change that simply doesn't exist in ordinary consciousness.
An independent editorial platform built on one premise: the people who need this information most deserve to receive it from the most credible source possible.
"Write like a brilliant science journalist who also lost a friend to PTSD and wants the world to understand what this medicine actually is."
Myco Brief covers the science, law, and human experience of psilocybin therapy. We are not a dispensary, a social media account, or an advocacy organization. We are the reference — the source that veterans, clinicians, journalists, and curious people link to when they need something they can trust.
We report what the research shows, in what populations, under what conditions. We do not tell readers what psilocybin will do for them — we tell them what clinical studies found.
Scientific rigour does not require scientific jargon. We translate the literature into plain language that a veteran, a worried family member, or a skeptical primary care physician can use.
We write for the reader who is not yet convinced. We write as if we are earning their belief through evidence — not assuming it, not demanding it.
No exceptions. If we cannot source it to a primary document, we do not publish it.
We cite the original study, not an article about the study. Links go to PubMed, OHA, ORS — not summaries.
Case studies are labeled as individual experience. Aggregate data is labeled as research.
We report what clinical studies found. We do not tell readers psilocybin will treat their depression or PTSD.
One factual CTA per article, placed contextually, never in the first third of any piece.
Myco Brief is an educational resource. For licensed psilocybin therapy services in Oregon, we partner with Psylowise — an OHA-licensed service center connecting people with qualified facilitators.
Peer-reviewed research on how psilocybin interacts with the brain — from default mode network disruption to long-term neuroplasticity. We cover the mechanisms, the imaging data, and what it means for treatment.
Psilocybin is a prodrug: the body converts it to psilocin, which binds primarily to 5-HT2A serotonin receptors in the prefrontal cortex. This binding disrupts the default mode network — a brain system associated with self-referential thinking, rumination, and rigid belief maintenance.
Unlike SSRIs, which modulate serotonin availability continuously, psilocybin produces a brief but profound change in brain connectivity. Regions that don't normally talk to each other begin communicating. Pathological patterns of rigidity temporarily dissolve.
The therapeutic window created by this disruption — typically 4–6 hours — is used by trained facilitators to help patients reprocess traumatic memories, shift entrenched beliefs, and access states of mind that are otherwise pharmacologically unreachable.
In November 2020, Oregon became the first state to create a regulated psilocybin services framework. Understanding exactly what the law permits — and what it doesn't — is essential for anyone considering access.
Measure 109 created two new license categories: psilocybin service centers and psilocybin facilitators. Both are regulated by the Oregon Health Authority. The law deliberately separates psilocybin services from the medical system — no prescription, diagnosis, or physician referral is required.
Clients must be 21 or older, undergo a preparation session with their facilitator before the service session, and remain on-site for the duration of the experience. Facilitators are required to be present throughout.
Critically, the law does not permit the sale of psilocybin products for home use, nor does it create any protection under federal law. Interstate transport of psilocybin — even to receive services in Oregon — remains federally illegal.
Veterans are disproportionately affected by treatment-resistant PTSD. The clinical evidence for psilocybin-assisted therapy in this population is among the strongest in the field. We cover it with the seriousness it deserves.
PTSD is characterized by a failure of fear extinction — the inability to update threat-associated memories even when the threat is gone. Standard treatments help many veterans process these memories. But for a significant subset, the memories remain stubbornly resistant to therapeutic intervention.
Psilocybin's disruption of the default mode network — the system that maintains rigid self-referential beliefs — creates a brief window in which traumatic memories can be revisited without the same activation of the fear response. Combined with a skilled facilitator and appropriate preparation, this window enables a kind of reprocessing that standard modalities haven't been able to achieve.
The MAPS Phase 3 data isn't a promise. But 67% symptom reduction in a treatment-resistant population, with no serious adverse events, is a result that deserves serious attention.
Anonymized clinical accounts and evidence-based narrative reporting on what psilocybin-assisted therapy looks like in practice — for people with PTSD, depression, end-of-life anxiety, and addiction.
Myco Brief's case study coverage is based on direct interviews with subjects, clinicians, or facilitators, cross-referenced against published literature where possible. All identifying details are altered or omitted with explicit subject consent.
We do not publish case studies that sensationalize the experience or that could reasonably be interpreted as promotional. Our editorial standard is the same as it would be for any medical or psychiatric reporting: accuracy, dignity, and honest representation of complexity.
If you have a story you'd like to share — as a client, facilitator, or clinician — you can reach our editorial team through the contact page.
Oregon Measure 109 created the first regulated psilocybin services framework in the United States. Here's how to navigate it — safely, legally, and with confidence.
Measure 109 created a services framework — not a medical one. You don't need a prescription or a diagnosis. You need to be 21 or older, willing to undergo a preparation session, and able to travel to Oregon.
The law is clear about what it doesn't permit: home use, mail-order, or possession outside a licensed center. But within those parameters, access is genuinely open.
Psylowise is a curated directory and booking platform for Oregon-licensed psilocybin service centers and facilitators. Every listing is verified against OHA records. You can search by location, specialty, approach, and availability.
Psilocybin-assisted therapy has the strongest evidence for treatment-resistant depression, PTSD, end-of-life anxiety, and certain addictions. It is not a first-line treatment and works best in combination with professional integration support. If you have a personal or family history of psychosis or are taking lithium, it may not be appropriate. A preparation session with a qualified facilitator is the right place to explore this question.
Yes — under Oregon law, sessions must occur at a licensed service center in Oregon. You can travel to Oregon from any state or country to access services. However, you cannot legally transport psilocybin across state lines. Colorado passed similar legislation in 2022 and is in the process of establishing its regulatory framework.
The Oregon Health Authority maintains a public registry of all licensed psilocybin facilitators and service centers at oregon.gov/oha. You can search by name or license number. Any facilitator operating legally in Oregon will have an OHA license and should be willing to share their license number on request.
Integration is the process of making meaning from what arose during your session — and translating insight into lasting behavioral change. The session itself creates a window of neuroplasticity. Integration work — through journaling, follow-up sessions, therapy, and intentional lifestyle changes — is what determines how much of that window is used productively. Most facilitators offer at least one integration session. Some offer ongoing support.
Yes. Veterans can access Oregon-licensed psilocybin services under the same terms as any other adult. The VA does not currently cover the cost. Several non-profit organizations offer subsidized or free access for veterans, including Heroic Hearts Project and Numinus Wellness Foundation. Some Oregon service centers offer veteran-specific scholarships — ask directly when you inquire.
Whether you're a veteran, a clinician, a curious person, or someone who's tried everything else — this is where to start. We've organized everything we know by topic.
Psilocybin-assisted therapy has a strong and growing evidence base. It also has real contraindications, real costs, and real risks when accessed outside a regulated setting.
Myco Brief does not advocate for illegal use of psilocybin. We cover the science, the law, and the human experience — accurately, without agenda.